LORATADINE TABLETS

The Defense Logistics Agency awarded a delivery order under base contract SPE2DX-25-D-9900 to DMS Pharmaceutical Group Inc. (CAGE 1UNB0) for the supply of 4 bottles of LORATADINE TABLETS, with a total contract value of $9.56. The award was issued on July 20, 2026, with delivery scheduled for August 4, 2026, to Fort Campbell, KY, under FOB destination terms, meaning the contractor bears all freight costs and risk until the item is received at the destination. The item is identified by NSN/Part number 6505015785988 and must be shipped using traceable methods, with no parcel post permitted, and each shipment must be labeled with the Traceable Control Number W51JR961980004 to ensure compliance with DoD logistics tracking requirements. Payment will be processed by DEF FIN AND ACCOUNTING SVC via remittance to P.O. Box 182317, Columbus, OH 43218-2317, using an accounting identifier of BX: 97X4930 SCBX0012620S33189, with invoicing likely handled through WAWF as standard for DLA. Inspection and acceptance occur at the delivery point and are the sole responsibility of the government, with no external quality standards explicitly cited beyond adherence to contract specifications and DoD pharmaceutical procurement norms. The contracting officer is Lisa Quinn, with Shari M. Cartagena serving as local administrator; no Contracting Officer’s Representative is named. The contract does not include any FAR clauses, special requirements, evaluation factors, or socioeconomic representations documented in the available materials, and no attachments or MIL-STDs are referenced. This transaction appears to be a minimal-value, administratively straightforward supply action under an existing IDIQ-type master contract.